PRNB News and Press, Principia Biopharma Inc. From 07/01/19

IsoRay ( ISR +3.2% ) initiated with Buy rating and $1 (138% upside) price target at Dawson James. More news on: IsoRay, Inc., United Therapeutics Corporation, Dr. Reddy's Laboratories Limited, Healthcare stocks news, Stocks on the move, , Read more ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Results from a Phase 1 clinical trial evaluating Principia Biopharma's ( PRNB +0.4% ) PRN1371 in 36 patients with advanced solid tumors showed a favorable safety profile and encouraging efficacy. The data were presented at the AACR Bladder Cancer: Transforming the Field meeting in ...

-- FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in metastatic urothelial carcinoma patients ongoing -- SOUTH SAN FRANCISCO, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical co...

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that...

SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that...

Principia Biopharma (NASDAQ: PRNB ): Q1 GAAP EPS of -$0.57 beats by $0.05 . More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced fina...

SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced th...

Principia Biopharma ( PRNB ) is a small-cap biopharma with its lead candidate in phase 3 targeting pemphigus vulgaris or PV, an autoimmune disease causing dermal or mucosal blisters. There are existing medications, but treatment may take years, so people often use a lower dose of medication no...